non-valvular atrial fibrillation
Cardiovascular · 2011–2013
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| apixaban Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation at moderate-to-high risk (defined by specific criteria including… | Mar 2013 | Not recommended | no section in document |
| rivaroxaban Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation who are inadequately controlled on warfarin or not suitable for… | Mar 2013 | Not recommended | no section in document |
| dabigatran etexilate Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation who are at moderate-to-high risk, evidenced by one or more risk… | Jul 2012 | Recommended | no section in document |
| rivaroxaban Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) who are at risk, as evidenced by prior stroke, TIA, or… | Mar 2012 | Recommended with restriction | unclear |
| rivaroxaban Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation at risk of stroke (prior stroke/TIA/non-CNS systemic embolism or… | Mar 2012 | Recommended with restriction | unclear |
| apixaban Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation who are at moderate-to-high risk of developing stroke or systemic… | Nov 2012 | Not recommended | no section in document |
| apixaban Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation at moderate-to-high risk of stroke or systemic embolism. | Nov 2012 | Not recommended | no section in document |
| rivaroxaban Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation who are inadequately controlled on warfarin or not suitable for… | Nov 2012 | Not recommended | no section in document |
| dabigatran etexilate Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation who are at moderate-to-high risk of developing stroke or systemic… | Mar 2011 | Recommended with restriction | no section in document |
| dabigatran etexilate Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation who are at moderate-to-high risk, evidenced by one or more risk… | Mar 2011 | Recommended | no section in document |
What the PBS pays
$437M in government benefit over 2024–25, across 7,276,071 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| apixaban | $308.7M |
| rivaroxaban | $128M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| edoxabanEdoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA355 | recommended | 2015-09 |
| apixabanApixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA275 | recommended | 2013-02 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.